Meeting Banner
Abstract #4240

Comparison of gadoterate meglumine and gadobutrol in MRI diagnosis of brain tumors: a double-blind randomized intra-individually controlled in cross-over study (the REMIND study)

Kenneth Maravilla1, Daniel San Juan Orta2, Sang Joon Kim3, and Guillermo Elizondo Riojas4

1Radiology, University of Washington, Seattle, WA, United States, 2Clinical Research Institute S.C., Tlanepantla de Baz, Mexico, 3Asan medical center / Radiology, Seoul, Korea, Democratic People's Republic of, 4Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Mexico

This double-blind randomized cross-over study was conducted to demonstrate non-inferiority of gadoterate meglumine vs. gadobutrol in MRI diagnosis of brain tumors. Images from two identical MRIs with each agent were evaluated by three independent off-site readers. Overall lesion visualization and characterization was scored as “good” or “excellent” in >90% of patients by all readers. Despite a small difference in signal intensity measurements in favor of gadobutrol, similar results were observed with the two agents regarding overall lesion visualization and characterization or qualitative efficacy criteria. Non-inferiority of gadoterate meglumine vs. gadobutrol in diagnosis of brain tumors by MRI was demonstrated.

This abstract and the presentation materials are available to members only; a login is required.

Join Here